Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2019 2020/C 123/07
Date: 2020-04-16
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, European Economic Area, free movement of goods, market approval, medicinal product, withdrawal from the market








C_2020123EN.01002101.xml










16.4.2020   


EN


Official Journal of the European Union


C 123/21






Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2019
(2020/C 123/07)

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2019, at their meeting on 25 October 2019:






Annex I


List of new marketing authorisations




Annex II


List of renewed marketing authorisations




Annex III


List of extended marketing authorisations




Annex IV


List of withdrawn marketing authorisations




Annex V


List of suspended marketing authorisations








ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2019:








EU-Number


Product


Country


Date of authorisation




EU/1/16/1138


Venclyxto


Norway


7.2.2019




EU/1/18/1291


Rizmoic


Liechtenstein


28.2.2019




EU/1/18/1291


Rizmoic


Norway


1.3.2019




EU/1/18/1291


Rizmoic


Iceland


21.2.2019




EU/1/18/1292


Apealea


Norway


7.1.2019




EU/1/18/1306


Symkevi


Liechtenstein


28.2.2019




EU/1/18/1317


Pazenir


Liechtenstein


30.6.2019




EU/1/18/1317


Pazenir


Norway


23.5.2019




EU/1/18/1317


Pazenir


Iceland


12.6.2019




EU/1/18/1325


Namuscla


Norway


3.1.2019




EU/1/18/1325


Namuscla


Iceland


9.1.2019




EU/1/18/1326


Flucelvax Tetra


Norway


4.1.2019




EU/1/18/1326


Flucelvax Tetra


Iceland


9.1.2019




EU/1/18/1331


Luxturna


Liechtenstein


28.2.2019




EU/1/18/1337


Macimorelin Aeterna Zentaris


Liechtenstein


28.2.2019




EU/1/18/1337


Macimorelin Aeterna Zentaris


Norway


23.1.2019




EU/1/18/1337


Macimorelin Aeterna Zentaris


Iceland


22.1.2019




EU/1/18/1338


Dengvaxia


Norway


4.1.2019




EU/1/18/1338


Dengvaxia


Iceland


8.1.2019




EU/1/18/1339


Bevespi Aeroshere


Norway


4.1.2019




EU/1/18/1339


Bevespi Aerosphere


Iceland


9.1.2019




EU/1/18/1341


Ogivri


Norway


4.1.2019




EU/1/18/1341


Ogivri


Iceland


8.1.2019




EU/1/18/1342


Erleada


Liechtenstein


28.2.2019




EU/1/18/1342


Erleada


Norway


23.1.2019




EU/1/18/1342


Erleada


Iceland


22.1.2019




EU/1/18/1343


Silodosin Recordati


Liechtenstein


28.2.2019




EU/1/18/1343


Silodosin Recordati


Norway


23.1.2019




EU/1/18/1343


Silodosin Recordati


Iceland


24.1.2019




EU/1/18/1344


Zirabev


Liechtenstein


28.2.2019




EU/1/18/1344


Zirabev


Norway


25.2.2019




EU/1/18/1344


Zirabev


Iceland


22.2.2019




EU/1/18/1345


Ondexxya


Liechtenstein


30.6.2019




EU/1/18/1345


Ondexxya


Norway


14.5.2019




EU/1/18/1345


Ondexxya


Iceland


14.6.2019




EU/1/18/1346


Miglustat Dipharma


Liechtenstein


28.2.2019




EU/1/18/1346


Miglustat Dipharma


Norway


1.3.2019




EU/1/18/1346


Miglustat Dipharma


Iceland


21.2.2019




EU/1/18/1347


Febuxostat Krka


Liechtenstein


30.4.2019




EU/1/18/1347


Febuxostat Krka


Norway


24.4.2019




EU/1/18/1347


Febuxostat Krka


Iceland


29.5.2019




EU/1/18/1348


Lusutrombopag Shionogi


Liechtenstein


28.2.2019




EU/1/18/1348


Lusutrombopag Shionogi


Norway


4.3.2019




EU/1/18/1348


Lusutrombopag Shionogi


Iceland


22.2.2019




EU/1/18/1349


Dectova


Liechtenstein


30.6.2019




EU/1/18/1349


Dectova


Norway


10.5.2019




EU/1/18/1349


Dectova


Iceland


26.6.2019




EU/1/18/1350


Tobramycin PARI


Liechtenstein


28.2.2019




EU/1/18/1350


Tobramycin PARI


Norway


1.3.2019




EU/1/18/1350


Tobramycin PARI


Iceland


22.2.2019




EU/1/18/1351


Trecondi


Liechtenstein


30.6.2019




EU/1/18/1351


Trecondi


Iceland


26.6.2019




EU/1/18/1352


Besremi


Liechtenstein


28.2.2019




EU/1/18/1352


Besremi


Norway


1.3.2019




EU/1/18/1352


Besremi


Iceland


19.2.2019




EU/1/19/1353


Atazanavir Krka


Liechtenstein


30.4.2019




EU/1/19/1353


Atazanavir Krka


Norway


16.4.2019




EU/1/19/1353


Atazanavir Krka


Iceland


26.4.2019




EU/1/19/1354


Vizimpro


Liechtenstein


30.4.2019




EU/1/19/1354


Vizimpro


Norway


8.4.2019




EU/1/19/1354


Vizimpro


Iceland


24.5.2019




EU/1/19/1355


Lorviqua


Liechtenstein


30.6.2019




EU/1/19/1355


Lorviqua


Norway


23.5.2019




EU/1/19/1355


Lorviqua


Iceland


12.6.2019




EU/1/19/1356


Idacio


Liechtenstein


30.4.2019




EU/1/19/1356


Idacio


Norway


12.4.2019




EU/1/19/1356


Idacio


Iceland


27.5.2019




EU/1/19/1357


Kromeya


Liechtenstein


30.4.2019




EU/1/19/1357


Kromeya


Norway


8.4.2019




EU/1/19/1357


Kromeya


Iceland


2.5.2019




EU/1/19/1358


AJOVY


Liechtenstein


30.4.2019




EU/1/19/1358


AJOVY


Norway


8.4.2019




EU/1/19/1358


AJOVY


Iceland


24.5.2019




EU/1/19/1360


Waylivra


Liechtenstein


30.6.2019




EU/1/19/1360


Waylivra


Norway


20.5.2019




EU/1/19/1360


Waylivra


Iceland


12.6.2019




EU/1/19/1361


Skyrizi


Liechtenstein


30.6.2019




EU/1/19/1361


Skyrizi


Norway


3.5.2019




EU/1/19/1361


Skyrizi


Iceland


4.6.2019




EU/1/19/1362


Palynzig


Norway


22.5.2019




EU/1/19/1362


Palynziq


Liechtenstein


30.6.2019




EU/1/19/1362


Palynziq


Iceland


4.6.2019




EU/1/19/1363


Zynquista


Liechtenstein


30.6.2019




EU/1/19/1363


Zynquista


Norway


27.5.2019




EU/1/19/1363


Zynquista


Iceland


29.5.2019




EU/1/19/1367


Zynteglo


Liechtenstein


30.6.2019




EU/1/19/1367


Zynteglo


Norway


7.6.2019




EU/1/19/1367


Zynteglo


Iceland


19.6.2019




EU/1/19/1368


Ambrisentan Mylan


Liechtenstein


30.6.2019




EU/1/19/1368


Ambrisentan Mylan


Norway


26.6.2019




EU/1/19/1368


Ambrisentan Mylan


Iceland


25.6.2019




EU/1/19/1369


Sixmo


Liechtenstein


30.6.2019




EU/1/19/1373


Doptelet


Liechtenstein


30.6.2019




EU/1/19/1373


Doptelet


Norway


26.6.2019




EU/1/19/1373


Doptelet


Iceland


28.6.2019




EU/1/19/1374


Esperoct


Norway


26.6.2019




EU/1/19/1374


Esperoct


Iceland


25.6.2019




EU/1/19/1377


Talzenna


Liechtenstein


30.6.2019




EU/1/19/1378


Temybric Ellipta


Norway


21.6.2019




EU/1/19/1378


Temybric Ellipta


Iceland


19.6.2019




EU/2/14/163


Versican Plus DHPPi/L4R


Liechtenstein


30.4.2019




EU/2/18/226


HorStem


Liechtenstein


30.6.2019




EU/2/18/226


HorStem


Norway


26.6.2019




EU/2/18/228


Arti-Cell Forte


Norway


8.5.2019




EU/2/18/231


Syvazul BTV


Norway


13.1.2019




EU/2/18/231


Syvazul BTV


Iceland


22.1.2019




EU/2/18/232


Isemid


Norway


13.1.2019




EU/2/18/232


Isemid


Iceland


24.1.2019




EU/2/18/233


EVANT


Liechtenstein


28.2.2019




EU/2/18/233


EVANT


Norway


20.2.2019




EU/2/18/233


EVANT


Iceland


21.2.2019




EU/2/18/234


Kriptazen


Liechtenstein


28.2.2019




EU/2/18/234


Kriptazen


Norway


20.2.2019




EU/2/18/234


Kriptazen


Iceland


20.2.2019




EU/2/19/235


Forceris


Liechtenstein


30.6.2019




EU/2/19/235


Forceris


Norway


15.5.2019




EU/2/19/235


Forceris


Iceland


20.6.2019




EU/2/19/236


Chanhold


Liechtenstein


30.6.2019




EU/2/19/236


Chanhold


Norway


27.6.2019




EU/2/19/236


Chanhold


Iceland


21.6.2019




EU/2/19/237


ReproCyc ParvoFLEX


Liechtenstein


30.6.2019




EU/2/19/237


ReproCyc ParvoFLEX


Norway


27.6.2019




EU/2/19/237


ReproCyc ParvoFLEX


Iceland


20.6.2019




EU/2/19/238


Felisecto Plus


Liechtenstein


30.6.2019




EU/2/19/238


Felisecto Plus


Norway


27.6.2019




EU/2/19/238


Felisecto Plus


Iceland


20.6.2019




EU/2/19/239


Baycox Iron


Liechtenstein


30.6.2019




EU/2/19/239


Baycox Iron


Norway


26.6.2019




EU/2/19/239


Baycox Iron


Iceland


21.6.2019




EU/2/19/240


Afoxolaner MERIAL


Liechtenstein


30.6.2019




EU/2/19/240


Afoxolaner MERIAL


Norway


27.6.2019









ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2019:








EU-Number


Product


Country


Date of authorisation




EU/1/08/498


Thymanax


Liechtenstein


28.2.2019




EU/1/08/498


Thymanax


Norway


28.1.2019




EU/1/08/498


Thymanax


Iceland


21.1.2019




EU/1/08/499


Valdoxan


Norway


3.1.2019




EU/1/08/499


Valdoxan


Iceland


8.1.2019




EU/1/08/502


Mepact


Liechtenstein


30.4.2019




EU/1/08/502


Mepact


Norway


7.3.2019




EU/1/08/502


Mepact


Iceland


20.3.2019




EU/1/09/521


Renvela


Liechtenstein


28.2.2019




EU/1/09/521


Renvela


Norway


7.3.2019




EU/1/09/521


Renvela


Iceland


4.3.2019




EU/1/09/524


Qutenza


Liechtenstein


30.4.2019




EU/1/09/524


Qutenza


Norway


8.4.2019




EU/1/09/524


Qutenza


Iceland


2.5.2019




EU/1/09/538


Afinitor


Liechtenstein


30.4.2019




EU/1/09/538


Afinitor


Norway


12.4.2019




EU/1/09/538


Afinitor


Iceland


30.4.2019




EU/1/09/564


Ilaris


Liechtenstein


30.6.2019




EU/1/09/564


Ilaris


Norway


20.6.2019




EU/1/09/564


Ilaris


Iceland


24.6.2019




EU/1/11/749


Caprelsa


Liechtenstein


28.2.2019




EU/1/11/749


Caprelsa


Norway


7.2.2019




EU/1/11/749


Caprelsa


Iceland


23.1.2019




EU/1/12/764


Pixuvri


Norway


20.6.2019




EU/1/12/764


Pixuvri


Iceland


24.6.2019




EU/1/13/818


Bosulif


Liechtenstein


28.2.2019




EU/1/13/818


Bosulif


Norway


26.2.2019




EU/1/13/818


Bosulif


Iceland


22.2.2019




EU/1/13/870


Orphacol


Liechtenstein


30.6.2019




EU/1/13/870


Orphacol


Norway


14.5.2019




EU/1/13/870


Orphacol


Iceland


11.6.2019




EU/1/13/875


Deltyba


Liechtenstein


30.4.2019




EU/1/13/875


Deltyba


Norway


23.4.2019




EU/1/13/875


Deltyba


Iceland


2.5.2019




EU/1/13/890


Cometriq


Liechtenstein


30.4.2019




EU/1/13/890


Cometriq


Iceland


14.6.2019




EU/1/13/896


Granupas


Liechtenstein


28.2.2019




EU/1/13/896


Granupas


Norway


4.1.2019




EU/1/13/896


Granupas


Iceland


9.1.2019




EU/1/13/901


Sirturo


Norway


17.1.2019




EU/1/13/901


Sirturo


Iceland


21.1.2019




EU/1/13/905


IZBA


Iceland


7.1.2019




EU/1/13/907


Adempas


Liechtenstein


28.2.2019




EU/1/13/907


Adempas


Norway


14.2.2019




EU/1/13/907


Adempas


Iceland


24.1.2019




EU/1/14/898


Anoro Ellipta


Liechtenstein


28.2.2019




EU/1/14/898


Anoro Ellipta


Norway


23.1.2019




EU/1/14/898


Anoro Ellipta


Iceland


23.1.2019




EU/1/14/899


Laventair Ellipta


Norway


23.1.2019




EU/1/14/899


Laventair Ellipta


Iceland


21.1.2019




EU/1/14/914


Vimizim


Liechtenstein


28.2.2019




EU/1/14/914


Vimizim


Norway


29.1.2019




EU/1/14/914


Vimizim


Iceland


30.1.2019




EU/1/14/915


Ebilfumin


Liechtenstein


28.2.2019




EU/1/14/915


Ebilfumin


Norway


14.3.2019




EU/1/14/915


Ebilfumin


Iceland


22.2.2019




EU/1/14/916


Pregabalin Pfizer


Iceland


10.1.2019




EU/1/14/917


Ulunar Breezhaler


Liechtenstein


28.2.2019




EU/1/14/917


Ulunar Breezhaler


Norway


23.1.2019




EU/1/14/917


Ulunar Breezhaler


Iceland


23.1.2019




EU/1/14/918


Vokanamet


Liechtenstein


28.2.2019




EU/1/14/918


Vokanamet


Norway


3.1.2019




EU/1/14/918


Vokanamet


Iceland


9.1.2019




EU/1/14/919


Hemangiol


Liechtenstein


28.2.2019




EU/1/14/919


Hemangiol


Norway


22.1.2019




EU/1/14/919


Hemangiol


Iceland


21.1.2019




EU/1/14/920


DuoResp Spiromax


Liechtenstein


30.4.2019




EU/1/14/920


DuoResp Spiromax


Norway


23.4.2019




EU/1/14/920


DuoResp Spiromax


Iceland


7.6.2019




EU/1/14/921


BiResp Spiromax


Liechtenstein


30.4.2019




EU/1/14/921


BiResp Spiromax


Norway


23.4.2019




EU/1/14/921


BiResp Spiromax


Iceland


7.6.2019




EU/1/14/922


Incruse Ellipta


Norway


23.1.2019




EU/1/14/922


Incruse Ellipta


Iceland


21.1.2019




EU/1/14/923


Entyvio


Norway


7.1.2019




EU/1/14/923


Entyvio


Iceland


9.1.2019




EU/1/14/928


Sylvant


Liechtenstein


30.4.2019




EU/1/14/928


Sylvant


Norway


29.4.2019




EU/1/14/928


Sylvant


Iceland


7.6.2019




EU/1/14/930


Jardiance


Liechtenstein


28.2.2019




EU/1/14/930


Jardiance


Norway


14.3.2019




EU/1/14/930


Jardiance


Iceland


19.2.2019




EU/1/14/931


Mekinist


Liechtenstein


28.2.2019




EU/1/14/931


Mekinist


Norway


25.2.2019




EU/1/14/931


Mekinist


Iceland


20.2.2019




EU/1/14/933


Simbrinza


Liechtenstein


28.2.2019




EU/1/14/933


Simbrinza


Norway


20.3.2019




EU/1/14/933


Simbrinza


Iceland


4.3.2019




EU/1/14/934


Plegridy


Liechtenstein


30.4.2019




EU/1/14/934


Plegridy


Norway


29.3.2019




EU/1/14/934


Plegridy


Iceland


5.6.2019




EU/1/14/935


Envarsus


Liechtenstein


30.6.2019




EU/1/14/935


Envarsus


Norway


25.6.2019




EU/1/14/935


Envarsus


Iceland


19.6.2019




EU/1/14/936


Nuwiq


Liechtenstein


30.6.2019




EU/1/14/936


Nuwiq


Norway


20.5.2019




EU/1/14/936


Nuwiq


Iceland


11.6.2019




EU/1/14/937


Gazyvaro


Liechtenstein


30.4.2019




EU/1/14/937


Gazyvaro


Norway


23.4.2019




EU/1/14/937


Gazyvaro


Iceland


7.6.2019




EU/1/14/938


Zydelig


Liechtenstein


30.6.2019




EU/1/14/938


Zydelig


Norway


8.5.2019




EU/1/14/938


Zydelig


Iceland


5.6.2019




EU/1/14/943


Velphoro


Liechtenstein


30.4.2019




EU/1/14/943


Velphoro


Norway


29.3.2019




EU/1/14/943


Velphoro


Iceland


28.3.2019




EU/1/14/946


Accofil


Norway


21.6.2019




EU/1/14/946


Accofil


Iceland


19.6.2019




EU/1/14/951


Busulfan Fresenius Kabi


Liechtenstein


30.6.2019




EU/1/14/951


Busulfan Fresenius Kabi


Iceland


27.6.2019




EU/1/14/987


Holoclar


Liechtenstein


28.2.2019




EU/1/14/987


Holoclar


Norway


5.2.2019




EU/1/14/987


Holoclar


Iceland


30.1.2019




EU/1/15/1078


Natpar


Norway


13.5.2019




EU/1/15/1078


Natpar


Iceland


11.6.2019




EU/1/16/1089


Pandemic influenza vaccine H5N1 AstraZeneca


Liechtenstein


30.6.2019




EU/1/16/1089


Pandemic influenza vaccine H5N1 AstraZeneca


Iceland


13.6.2019




EU/1/16/1139


Ocaliva


Norway


7.1.2019




EU/1/16/1139


Ocaliva


Iceland


9.1.2019




EU/1/16/1139


Ocaliva


Liechtenstein


28.2.2019




EU/1/17/1214


Bavencio


Liechtenstein


30.6.2019




EU/1/17/1214


Bavencio


Norway


27.6.2019




EU/1/17/1214


Bavencio


Iceland


27.6.2019




EU/1/17/1250


Rubraca


Norway


21.3.2019




EU/1/17/1250


Rubraca


Iceland


21.3.2019




EU/2/08/090


Loxicom


Liechtenstein


28.2.2019




EU/2/08/090


Loxicom


Norway


20.2.2019




EU/2/08/090


Loxicom


Iceland


31.1.2019




EU/2/09/099


Suvaxyn PCV


Liechtenstein


30.6.2019




EU/2/09/099


Suvaxyn PCV


Iceland


19.6.2019




EU/2/09/099


Suvaxyn PCV


Norway


11.6.2019




EU/2/13/158


Bravecto


Liechtenstein


28.2.2019




EU/2/13/158


Bravecto


Norway


20.2.2019




EU/2/13/158


Bravecto


Iceland


20.2.2019




EU/2/13/159


NexGard


Norway


15.1.2019




EU/2/13/159


NexGard


Iceland


10.1.2019




EU/2/13/160


Fungitraxx


Liechtenstein


30.4.2019




EU/2/13/160


Fungitraxx


Norway


12.4.2019




EU/2/13/160


Fungitraxx


Iceland


27.3.2019




EU/2/14/161


Equisolon


Liechtenstein


28.2.2019




EU/2/14/161


Equisolon


Norway


12.2.2019




EU/2/14/161


Equisolon


Iceland


15.2.2019




EU/2/14/162


Parvoduk


Norway


17.1.2019




EU/2/14/162


Parvoduk


Iceland


15.1.2019




EU/2/14/163


Versican Plus DHPPi/L4R


Norway


23.4.2019




EU/2/14/164


Versican Plus DHPPi/L4


Liechtenstein


30.4.2019




EU/2/14/164


Versican Plus DHPPi/L4


Norway


23.4.2019




EU/2/14/165


Vectra Felis


Liechtenstein


28.2.2019




EU/2/14/165


Vectra Felis


Norway


20.2.2019




EU/2/14/165


Vectra Felis


Iceland


20.2.2019




EU/2/14/166


ERYSENG


Liechtenstein


30.6.2019




EU/2/14/166


ERYSENG


Norway


24.6.2019




EU/2/14/166


ERYSENG


Iceland


19.6.2019




EU/2/14/167


ERYSENG PARVO


Liechtenstein


30.6.2019




EU/2/14/167


ERYSENG PARVO


Norway


21.5.2019




EU/2/14/167


ERYSENG PARVO


Iceland


19.6.2019




EU/2/14/168


Versican Plus Pi


Liechtenstein


30.4.2019




EU/2/14/168


Versican Plus Pi


Norway


23.4.2019




EU/2/14/168


Versican Plus Pi


Iceland


13.6.2019




EU/2/14/169


Versican Plus DHPPi


Norway


23.4.2019




EU/2/14/169


Versican Plus DHPPi


Iceland


13.6.2019




EU/2/14/171


Versican Plus L4


Liechtenstein


30.4.2019




EU/2/14/171


Versican Plus L4


Norway


23.4.2019




EU/2/14/171


Versican Plus L4


Iceland


14.6.2019




EU/2/14/173


Versican Plus Pi/L4R


Liechtenstein


30.6.2019




EU/2/14/173


Versican Plus Pi/L4R


Norway


20.6.2019




EU/2/14/173


Versican Plus Pi/L4R


Iceland


19.6.2019




EU/2/14/174


Nobilis IB Primo QX


Norway


24.6.2019




EU/2/14/174


Nobilis IB Primo QX


Iceland


19.6.2019




EU2/14/172


Versican Plus Pi/L4


Norway


24.4.2019




EU2/14/172


Versican Plus Pi/L4


Iceland


14.6.2019









ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2019:








EU-Number


Product


Country


Date of authorisation




EU/1/02/204/002


Trisenox


Norway


21.6.2019




EU/1/02/204/002


Trisenox


Iceland


20.6.2019




EU/1/07/389/013-014


Orencia


Norway


24.4.2019




EU/1/07/389/013-014


Orencia


Iceland


18.6.2019




EU/1/09/546/009


Simponi


Norway


18.2.2019




EU/1/09/546/009


Simponi


Iceland


21.2.2019




EU/1/15/1046/008-010


Elocta


Iceland


8.1.2019




EU/1/15/1059/006-007


Orkambi


Norway


23.1.2019




EU/1/15/1059/006-007


Orkambi


Iceland


23.1.2019




EU/1/15/999/004


Zykadia


Norway


11.4.2019




EU/1/15/999/004


Zykadia


Iceland


13.6.2019




EU/1/16/1168/005-007


Vihuma


Iceland


10.1.2019




EU/1/17/1229/009-016


Dupixent


Norway


21.5.2019




EU/1/17/1229/009-016


Dupixent


Iceland


19.6.2019




EU/1/18/1293/004-006


Aimovig


Norway


20.5.2019




EU/1/18/1293/004-006


Aimovig


Iceland


18.6.2019









ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2019:








EU-Number


Product


Country


Date of withdrawal




EU/1/01/186


Nonafact


Norway


20.6.2019




EU/1/01/186


Nonafact


Iceland


20.6.2019




EU/1/01/191


Ketek


Norway


20.6.2019




EU/1/01/191


Ketek


Iceland


25.6.2019




EU/1/05/325


Macugen


Norway


4.1.2019




EU/1/05/325


Macugen


Iceland


10.1.2019




EU/1/06/355


ATryn


Norway


8.3.2019




EU/1/06/355


ATryn


Iceland


4.3.2019




EU/1/06/358


Silgard


Norway


18.2.2019




EU/1/06/358


Silgard


Iceland


19.3.2019




EU/1/07/390


Altargo


Norway


26.2.2019




EU/1/09/536


Topotecan Actavis


Liechtenstein


28.2.2019




EU/1/09/536


Topotecan Actavis


Norway


6.2.2019




EU/1/09/536


Topotecan Actavis


Iceland


22.1.2019




EU/1/09/552


Topotecan Teva


Iceland


29.5.2019




EU/1/10/625


Arzerra


Norway


25.2.2019




EU/1/10/625


Arzerra


Iceland


5.3.2019




EU/1/10/651


Clopidogrel HCS


Liechtenstein


30.6.2019




EU/1/10/651


Clopidogrel HCS


Norway


20.6.2019




EU/1/10/651


Clopidogrel HCS


Iceland


20.6.2019




EU/1/13/849


Somatropin Biopartners


Iceland


1.2.2019




EU/1/13/876


Imatinib Medac


Norway


26.2.2019




EU/1/13/876


Imatinib medac


Iceland


22.2.2019




EU/1/14/932


Vantobra


Norway


26.2.2019




EU/1/14/932


Vantobra


Iceland


21.2.2019




EU/1/15/1044


Numient


Norway


24.4.2019




EU/1/15/1044


Numient


Iceland


2.5.2019




EU/1/16/1100


Palonosetron Hospira


Liechtenstein


30.6.2019




EU/1/16/1123


Airexar Spiromax


Norway


14.5.2019




EU/1/16/1123


Airexar Spiromax


Iceland


29.5.2019




EU/1/17/1206


Rituzena


Norway


14.5.2019




EU/1/17/1206


Rituzena


Iceland


29.5.2019




EU/1/17/1240


Cyltezo


Norway


6.2.2019




EU/1/17/1240


Cyltezo


Iceland


22.1.2019




EU/2/13/155


Trifexis


Iceland


1.2.2019




EU/2/17/208


Ingelvac PCV FLEX


Iceland


28.6.2019









ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2019:








EU-Number


Product


Country


Date of suspension